Khona Scientific and Bright Path Launched Drug Project
The partnership aims to establish domestic end-to-end manufacturing for taxane-based oncology medicines.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Should the U.S. prioritize domestic manufacturing to secure the supply of essential medicines?
Khona Scientific and Bright Path have announced Project bioFORxGE, a collaborative effort to build a domestic supply chain for taxane-based drugs. The project uses a new integrated manufacturing process to produce finished injectable drug products.
Why it matters
The collaboration seeks to mitigate vulnerabilities in the domestic drug supply chain by replacing reliance on external sources for critical cancer treatments. It addresses the need for secure access to essential APIs within the United States.
The initiative targets three primary milestones to optimize a workflow moving from renewable sugar feedstocks to finished taxane products. This replaces traditional reliance on imported precursors by utilizing biosynthetic 10-DAB produced via the BiDS platform.
The players
Khona Scientific
A developer of biosynthetic platforms focused on the production of precursors for complex pharmaceutical compounds.
Bright Path
A manufacturing technology company specializing in continuous-flow chemical reactors for API production.
The details
Project bioFORxGE links biosynthetic Key Starting Material (KSM) production with continuous-flow chemisynthesis—a method of chemical production where materials flow through reactors without interruption. Khona Scientific uses its BiDS (Biosynthetic Development System) platform to create 10-DAB from renewable domestic sugar. Bright Path then uses STT (Sequential Transition Technology) reactors to convert that precursor into the final Paclitaxel Active Pharmaceutical Ingredient (API).
Timeline
October 13, 2026: Companies announced the creation of Project bioFORxGE.
The Tech Race
The project follows a broader industry trend toward localized, continuous-flow manufacturing designed to reduce dependency on global supply chains. It acts as a direct effort to secure domestic production of essential oncology drugs following recent identified vulnerabilities.
The initiative currently focuses on establishing the manufacturing capability for Paclitaxel, with plans to expand the process to docetaxel and cabazitaxel in the future. Once operational, this domestic pipeline is intended to improve the reliability of supply for these common oncology agents.
The takeaway
The project represents a shift toward synthetic biology-integrated manufacturing to ensure the stability of oncology drug supplies. Watch for upcoming announcements regarding the scaling of the process to docetaxel and cabazitaxel production.
Further reading
For broader trends in localized drug production, visit our Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should the U.S. prioritize domestic manufacturing to secure the supply of essential medicines?
